AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04429932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu flavor F_1.2
Description: Fse of Myblu e-cigarette with flavor F at 1.2% nicotine
Study NCT04429932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu flavor G_2.4
Description: Use of Myblu e-cigarette with flavor G at 2.4% nicotine
Study NCT04429932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu flavor H_2.4
Description: Use of Myblu e-cigarette with flavor H at 2.4% nicotine
Study NCT03389672 — intervention group
Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: For conventional spinal anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
Study NCT03389672 — intervention group
Intervention type: PROCEDURE
Intervention: epidural anesthesia
Description: For conventional epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
Study NCT03389672 — intervention group
Intervention type: PROCEDURE
Intervention: combined spinal-epidural anesthesia
Description: For conventional combined spinal-epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
Study NCT03504033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: inhalation to maintain anesthesia
Study NCT03504033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: inhalation to maintain anesthesia
Study NCT02426866 — intervention group
Intervention type: DRUG
Intervention: Efavirenz
Study NCT04334941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04334941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04334941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04334941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04334941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04334941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04334941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT02828033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
Study NCT00809250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-K562/leukemia cell vaccine
Description: Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
Study NCT04489641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Description: Psychological treatment
Study NCT04489641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: Pharmacological intervention
Study NCT01704859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo
Study NCT01704859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo
Study NCT01704859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT01704859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT01704859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Study NCT01704859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.
Study NCT03554239 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: genotyping
Description: Blood sample
Study NCT01301326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subthreshold and threshold laser treatment
Description: subthreshold laser treatment
Study NCT01301326 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold laser treatment
Description: threshold laser treatment
Study NCT00968344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 3-4g Leucine added to daily meals
Study NCT00968344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Powered amino acid
Study NCT04820192 — intervention group
Intervention type: OTHER
Intervention: Craniosacral Therapy
Description: The Upledger method of applying both specific and non-specific manual therapy of gentle, sustained, non-invasive stretch to soft tissues of fascia, meninges and osseous attachments. Fluid exchange is also believed to be a resulting result of CST. Treatment is applied to myofascial and osseous sites over the entire body, tending to specific and unique constellation of tissue restrictions and osseous compressions of soft tissue.
Study NCT02035384 — intervention group
Intervention type: DRUG
Intervention: turoctocog alfa
Description: Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.
Study NCT01925521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part1 : OPS-2071
Description: single oral dose under fasted condition
Study NCT01925521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part1 : Placebo of OPS-2071
Description: single oral dose under fasted condition
Study NCT01925521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part2 : OPS-2071
Description: multiple twice-daily oral dosing for 5-7days
Study NCT01925521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part2 : Placebo of OPS-2071
Description: multiple twice-daily oral dosing for 5-7days
Study NCT02912871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIgHIFU unilateral subthalamotomy
Description: High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
Study NCT01586091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine Oral Tablet
Study NCT01586091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine 60 Mg Oral Tablet
Study NCT01586091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT01586091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT03319550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: see experimental description
Study NCT03319550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: see experimental description
Study NCT03319550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched whey
Description: see experimental description
Study NCT01748760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLASP-A intervention
Description: Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
Study NCT04537897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 474121
Description: BI474121
Study NCT04537897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study NCT01748760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Referral to outpatient treatment as part of routine discharge planning.
Study NCT02085655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaspargase
Description: pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02085655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02085655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT04537897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam
Study NCT04537897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04463784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 400Mg Oral Tablet
Description: The experimental arm will receive 400mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
Study NCT02085655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
Study NCT02085655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02085655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02085655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100-200mg, PO, after chemotherapy
Study NCT01769521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensimed Triggerfish®
Description: Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
Study NCT02522377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: inter venous injections
Study NCT02522377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: inter venous injections
Study NCT02503891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MP-1 Polymer on Ceramic Articulation system
Description: MP-1 Polymer liner on Ceramic head
Study NCT04292938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate ketogenic diet
Description: Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
Study NCT03770143 — intervention group
Intervention type: OTHER
Intervention: Feeding with palm olein formula
Study NCT03977077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin binding taxol
Description: 125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
Study NCT04463784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 600Mg Oral Tablet
Description: The active comparator arm will receive 600mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
Study NCT05177523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Each enrolled subject will undergo a MRI at baseline and a second MRI at 2 years (+/- 3 months) follow-up.
Study NCT00583739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
Study NCT05177523 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive examination for healthy subjects
Description: Neurocognitive examination for healthy subjects will be performed at both baseline and follow-up
Study NCT05177523 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: Each enrolled subject will undergo a blood sampling (10 ml) at baseline
Study NCT01163435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose dual therapy
Description: rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
Study NCT01163435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sequential therapy
Description: rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
Study NCT01163435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin-based triple therapy
Description: rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
Study NCT01163435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin-based triple therapy
Description: rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
Study NCT00629122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Arm B)
Description: Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
Study NCT00629122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole Troche
Description: Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
Study NCT00629122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Arm A)
Description: Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
Study NCT00629122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin Suspension
Description: Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
Study NCT03469843 — intervention group
Intervention type: OTHER
Intervention: Non intervention
Description: patients without intervention
Study NCT00684697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: iron
Description: High, intermediate and low iron dosage orally for 2 months
Study NCT00684697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron
Description: High, intermediate and low iron dosage orally for 2 months
Study NCT00684697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron
Description: High, intermediate and low iron dosage orally for 2 months
Study NCT00926887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia(R) EML Laser
Description: Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
Study NCT00926887 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Laser
Description: Inactive light
Study NCT02300103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily
Study NCT02300103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT04277403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost
Description: Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.
Study NCT04277403 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Single session or hypofractionated stereotactic radiosurgery
Description: Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.
Study NCT01192698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV interferon
Description: IV interferon 5MU during anhepatic phase
Study NCT01647685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanocort
Description: Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
Study NCT01647685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
Study NCT01647685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
Study NCT02736812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: French Lyophilized Plasma
Description: During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of FLYP
Study NCT02736812 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normale Saline Solution
Description: During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of Normale Saline Solution